Clinical trial · Interventional
Resection or Ablation of Small Kidney Tumors
Resection or Ablative Treatment of Small Renal Tumors, a Multicenter Randomized Clinical Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Ablative treatments are believed to have a lower rate of complications, shorter hospital stays, and fewer interventions with benign PAD compared to partial nephrectomies in small kidney cancer lesions. The purpose of the study is to compare complications, the frequency of residual tumors, impact on kidney function, differences in quality of life, and health economic factors in a randomised study. We will also compare the oncological outcomes, including survival and recurrence of kidney cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Kidney Cancer | Malignant Kidney Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ablation | Procedure | — | UNRESOLVED |
| Surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Ablation
- description
- Ablative treatment of small kidney cancer lesion, could be given with radiofrequency, microwawe or cryoablation
- interventionNames
- Procedure: Ablation
- type
- ACTIVE_COMPARATOR
- label
- Partial nephrectomy
- description
- Surgical resection with open or laparoscopic technique
- interventionNames
- Procedure: Surgery
Primary outcomes (3)
- measure
- Number of participants with surgical complications according to Clavien-Dindo grade 2-5
- timeFrame
- First year after inclusion
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 - 99 years * Patient suitable based on clinical status for both ablative treatment and surgery * Primary kidney tumor * Tumor size ≤ 3 cm * Clinical stage of the tumor T1a (no macroscopic vascular or extrarenal invasion) * Tumor location suitable for both ablative treatment and resection * Absence of radiological signs of metastasis * Biopsy with malignant pathological analysis (PAD) * ISUP grade I-III" Exclusion Criteria: * Radiological signs of metastasis * Synchronous kidney tumors * ISUP grade IV or sarcomatoid growth in the biopsy * Other metastasized cancer in the last 5 years * Patient unable to make an informed decision to participate in the study
References
Publications (0)
Data not yet available